- About us
- About Vaccines
- Media centre
- Become a member
Effective vaccination programmes ease pressure on budgets and allow resources to focus on other healthcare areas and medical innovation
Vaccination at the Heart of Public Health. Vaccines Europe calls on EU policy-makers to develop a comprehensive vaccination strategy through five core policy asks.
How long for a vaccine to reach European Population? 6,4 years is the median time lag between marketing authorisation and effective population access
With 47% growth in R&D investment over the past eight years and over 70% of current R&D projects based on new antigens and new combinations, Vaccines Europe members highly contribute to innovation.
As the EU-wide recognised vaccine industry stakeholder, Vaccines Europe represents major innovative research-based vaccine companies operating in Europe and is currently expanding to SMEs.
Find out more about our services, the opportunites we offer and how to become a member.
On 24–30 April 2016, Europe celebrates the European Immunization Week with the aim of increasing vaccination coverage by raising awareness of the importance of immunisation among parents and caregivers, health care professionals, policy- and decision-makers, and the media.
“This week should give us the opportunity to raise the importance of immunisation as a critical public health intervention and the value that immunisation represents in terms of health and economic returns,” said the Vaccines Europe president, Andrea Rappagliosi. “And in this respect we would like to see more activities organised at EU and national level during European Immunization Week.”
The “Innovation Partnership for a Roadmap on Vaccines in Europe” (IPROVE) – financed under the EU 7th Framework Programme (FP7) – today launched a strategy setting out a vision for vaccine research and innovation in Europe over the next 20 years.
The roadmap, which is the first of its kind, was launched during a special European Parliament event that took place on the 16th of March and was hosted by MEPs Francoise Grossetête, Cristian-Silviu Busoi and Markus Ferber. Key opinion leaders in the field of vaccine research and development attended the event including representatives from the European Commission, the European Parliament, European Union Member States and a broad representation of the vaccines community including academia, industry, civil society and regulatory bodies. Read more…
Vaccines Europe welcomes the report on “Vaccines and alternative approaches: reducing our dependence on antimicrobials” published today by the UK Government-commission O’Neill AMR review.
The report addresses in a clear way the fundamental importance of the role that vaccines can play in the global fight against anti-microbial resistance. Vaccines Europe considers that any national or supra national action plan to fight the rising threat of antimicrobial resistance should first look at all possible measures that can be implemented to prevent infections. Read more…